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ABSTRACT 
Objective: The influence of confounding neurocognitive comorbidities in persons living with 
HIV (PLWH) on neuroimaging has not been systematically evaluated. We determined 
associations between comorbidity burden and brain integrity and examined the moderating 
effect of age on these relationships. 
Design: Observational, cross-sectional substudy of the CNS HIV Antiretroviral Therapy 
Effects Research (CHARTER) cohort. 
Methods: 288 PLWH (mean age=44.2) underwent structural MRI and MR spectroscopy as 
well as neurocognitive and neuromedical assessments. Consistent with Frascati criteria for 
HIV-associated neurocognitive disorders (HAND), neuromedical and neuropsychiatric 
comorbidity burden was classified as incidental (mild), contributing (moderate), or 
confounding (severe-exclusionary) to a diagnosis of HAND. Multiple regression modeling 
predicted neuroimaging outcomes as a function of comorbidity classification, age, and their 
interaction. 
Results: Comorbidity classifications were 176 incidental, 77 contributing, and 35 
confounded; groups did not differ in HIV disease characteristics. Relative to incidental and 
contributing participants, confounded participants had less cortical gray matter and more 
abnormal white matter and ventricular CSF, alongside more neuroinflammation (choline, 
myo-inositol) and less neuronal integrity (N-acetylaspartate). Older age exacerbated the 
impact of comorbidity burden: to a greater extent in the confounded group, older age was 
associated with more abnormal white matter (p=.017), less total white matter (p=.015), and 
less subcortical gray matter (p=.014).  
Conclusions: Neuroimaging in PLWH reveals signatures associated with confounding 
neurocognitive conditions, emphasizing the importance of evaluating these among 
individuals with suspected HAND. Older age amplifies subcortical and white matter tissue 
injury, especially in PLWH with severe comorbidity burden, warranting increased attention 
to this population as it ages. 
Key Words: HIV, comorbidity, aging, brain, MRI, MRS, neurocognitive disorders 
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INTRODUCTION 
Combination antiretroviral therapy (cART) increases life expectancy among people 
living with HIV (PLWH)[1], with a rising rate of PLWH aged 50 and older[2]. Nevertheless, 
milder forms of HIV-associated neurocognitive disorders (HAND)[1, 3, 4], neuroimaging 
abnormalities[5], and comorbidities[6] remain prevalent in the cART-era. Frascati criteria for 
HAND require that neurocognitive impairment be at least partially attributable to HIV-
infection, and provide guidelines for comorbidity review[7]. Clinical judgement is required to 
determine the extent to which non-HIV-related comorbidities influence interpretation of 
neurobehavioral assessment, with a severe comorbidity classification precluding a diagnosis 
of HAND[1, 7].  
Given the high prevalence of comorbidities that may compromise CNS integrity 
among PLWH, some authors have questioned whether reported rates of HAND are inflated[6]. 
While severe comorbidity burden enhances risk for neurocognitive impairment in PLWH[1, 8], 
prevalence of HAND in PLWH with minimal-to-moderate comorbidity burden ranges from 
19% to 50%[1, 9, 10].  Comorbidities may be particularly damaging among older PLWH, who 
are at increased risk for HAND[11, 12], brain atrophy[13], and acquisition of age-related 
comorbidities[14]. 
Structural MRI and MR spectroscopy (MRS) studies demonstrate HIV-related 
structural and neurochemical alterations to both cortical and subcortical gray and white 
matter tissues[5, 15]. We have previously reported on neuroimaging signatures of PLWH 
without major neurocognitive confounds[16, 17]. However, neuroimaging correlates of Frascati-
based comorbidity classifications have not been systematically evaluated. Thus, we examined 
the impact of three levels of comorbidity burden (i.e., mild, moderate, and severe) on 
neuroimaging measures of brain integrity, as well as the potential moderating effect of age on 
these relationships.  
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METHODS 
Participants 
 Participants included 288 English-speaking PLWH from the neuroimaging substudy 
of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) investigation[1, 16], 
drawn from five university centers: Johns Hopkins University (Baltimore, MD, n=50); Icahn 
School of Medicine at Mount Sinai (New York, NY, n=65); University of California at San 
Diego (San Diego, CA, n=80); University of Texas Medical Branch (Galveston, TX, n=59); 
and University of Washington (Seattle, WA, n=34). CHARTER was structured to examine 
and follow individuals who were as representative as possible of the population of adults 
living with HIV and receiving primary care at US university-based clinics; as such, potential 
participants were not excluded on the basis of comorbid conditions that may affect brain 
structure and function. All participants completed a cross-sectional evaluation consisting of a 
blood draw, comprehensive neurobehavioral and neuromedical assessments, and scanning 
protocols for MRS and structural MRI. All scans occurred between May 2004 and August 
2007. Procedures were approved by local Institutional Review Boards (IRBs) and all 
participants provided written informed consent.  
Comorbidity Classifications 
In accordance with published Frascati criteria for HAND and guidelines for reviewing 
developmental and neuromedical histories[7], each case was reviewed by a senior clinician 
(R.K.H.) to determine whether neuromedical and neuropsychiatric comorbidity burden was 
“incidental” (normal/mild), “contributing” (moderate), or “confounding” (severe) to a 
diagnosis of HAND[1]. In order to adequately classify comorbidity burden, clinical judgment 
is required to determine their severity, potential influence on neurocognitive performance and 
everyday functioning, and timing in relation to the course of HIV disease. Interrater 
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reliability of the comorbidity classifications was previously assessed using independent 
ratings for 269 patients from another CHARTER clinician-investigator (D.B.C.)[1]. Seventy-
four percent of these independent classifications were identical. Of the original 269 
classifications, only 7% changed after discussion and less than 5% resulted in a change in 
HAND classification (change to or from confounding). Of the 288 participants in this 
substudy, comorbidity classifications were 61% (n=176) incidental, 27% (n=77) contributing, 
and 12% (n=35) confounding. Confounded cases consisted of participants with severe 
comorbidities (e.g., neurodevelopmental, cerebrovascular, systemic medical, and substance-
related) that could sufficiently explain all observed neurocognitive or everyday functioning 
impairments, thus precluding a HAND diagnosis (see Table 1 for frequency of selected 
comorbidities across classification groups).  
Neuromedical Assessment 
All participants underwent structured medical and neurological examinations that 
included a comprehensive history inclusive of medication utilization, and venipuncture. A 
subset of participants (n=175) underwent a lumbar puncture for CSF collection. Routine 
clinical chemistry panels, complete blood counts, rapid plasma reagin, hepatitis C virus 
antibody, and CD4+ T cell enumerations were performed at each site's Clinical Laboratory 
Improvement Amendments (CLIA)–certified, or CLIA equivalent, medical center laboratory. 
HIV RNA concentration in plasma and CSF were measured using reverse transcriptase-
polymerase chain reaction (Roche Amplicor, v. 1.5, with a lower limit of quantitation 50 
copies/ml).  
Neurocognitive Assessment 
All participants completed a comprehensive neurocognitive test battery, covering 
seven cognitive domains commonly impacted by HIV-related brain dysfunction. Normative 
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standards were used to correct for effects of age, education, gender, and race/ethnicity, as 
appropriate[4]. Individual test scores were converted to demographically-corrected T scores 
and associated deficit scores within each domain to determine domain-specific impairment[1]. 
Participants with at least mild impairment in two or more of the seven neurocognitive 
domains were classified as neurocognitively impaired, in accordance with Frascati criteria[7]. 
Psychiatric Assessment 
 Current mood symptoms were assessed using the Beck Depression Inventory II (BDI-
II)[18]. The computer-based Composite International Diagnostic Interview (CIDI) was 
administered to determine DSM-IV diagnoses of current and lifetime substance use and mood 
disorders[19]. 
Neuroimaging Assessments  
MR imaging was performed on six General Electric 1.5-Tesla scanners at five sites 
using the same sequences, and scanner performance was annually reviewed in person for 
quality through review of human phantom data; in addition, because scanner differences (e.g., 
hardware, software, head coil upgrades) can influence neuroimaging metrics, we included a 
“scanner” variable in statistical analyses to account for scanner-related effects[20] as in our 
prior work[16, 21]. Four series were acquired for structural morphometric analysis, including 
coronal two-dimensional T2- and proton-density (PD)-weighted fast spin echo sequences 
(section thickness=2.0 mm), and three-dimensional sagittal T1- and PD-weighted spoiled 
gradient recalled acquisitions (section thickness=1.3 mm)[16, 21]. MRS was performed using a 
standardized point-resolved spectroscopy protocol (echo time=35ms, repetition 
time=3000ms)[22]. 
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Multi-channel Structural MRI:  As described previously[16, 21], we used the multi-
channel dataset in a semi-automated workflow to measure cortical and subcortical gray 
matter; total cerebral and abnormal (e.g., hyperintense regions on T2-weighted images) white 
matter; and ventricular and cerebral sulcal CSF, as well as supra-tentorial cranial vault 
volume to account for individual differences in head size. The workflow includes image 
inspection for motion and other artifacts, re-slicing to a standard space, intra-subject mutual 
information registration, bias-correction with nonparametric non-uniformity normalization, 
removal of non-brain tissue, three-tissue segmentation (gray matter, white matter, and CSF), 
abnormal white matter designation, and anatomical labeling performed by trained anatomists. 
This approach includes the identification of regions of cerebral white matter with abnormal 
MRI signal characteristics; these regions segmented as gray matter, but are anatomically 
located within the white matter. 
Single-Voxel MRS:  As described previously[22], three regional voxels were acquired: 
frontal gray matter (FGM; 20x20x20mm and 64 acquisitions), frontal white matter (FWM; 
20x20x20mm and 64 acquisitions), and basal ganglia (BG; 20x20x15mm and 96 
acquisitions). MRS concentrations of N-acetylaspartate, choline, myo-inositol, and creatine 
were quantified using LCModel with water suppression[23]. Water suppression allows for the 
examination of absolute metabolite levels, our primary measures of interest; although ratios 
to creatine have been commonly reported with the aim to provide standardization across sites 
and studies, this approach has limitations and there is evidence that HIV infection 
independently affects creatine levels directly, confounding the interpretation of ratio values 
and existing findings[as in 22, 24]. Only metabolite estimates for appropriately placed voxels with 
adequate spectra (standard deviation<21) were used; therefore, sample size varied by MRS 
region or metabolite. Structural segmentation was used to estimate the proportion of relevant 
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tissue volume within each MRS voxel (e.g., amount of gray matter in FGM voxel) to control 
for individual sampling variability. 
Statistical Analysis 
 Comorbidity group differences on demographics, HIV disease characteristics, 
neurocognitive impairment, and comorbid conditions were examined using ANOVA, 
Kruskal-Wallis, or Chi-square tests as appropriate. For significant omnibus results, pair-wise 
comparisons were conducted using Tukey’s Honest Significant Difference (HSD) tests for 
continuous outcomes and Bonferroni-corrections for categorical outcomes.  
 A series of multivariable linear regression models was used to model each structural 
MRI and MRS measure as a function of comorbidity group, age, and their interaction, 
covarying for scanner. Comorbidity status was dummy coded with confounded participants 
serving as the reference group. Supratentorial cranial volume was included as a covariate in 
structural MRI analyses to control for individual differences in head size. Similarly, the 
proportion of relevant tissue volume within each voxel (e.g., amount of gray matter in FGM) 
was included as a covariate for MRS analyses to control for individual sampling variability. 
Models lacking a significant comorbidity and age interaction were re-run without interaction 
terms to estimate the independent effect of age across the whole sample. For models with 
significant comorbidity group by age interactions, we added individual comorbidities that 
differed in prevalence across age as covariates to examine potential attenuation of age-related 
comorbidity group effects. To shed light on findings in the present study, exploratory 
analyses also examined whether the interactive effects of age and individual comorbid 
conditions followed the pattern of overall comorbidity group by age interaction effects. 
Standardized betas are presented to enhance interpretability of comorbidity group and age 
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effects across imaging outcomes. All analyses were performed using JMP Pro version 12.0.1 
(JMP®, Version <12.0.1>, SAS Institute Inc., Cary, NC, 1989-2007).  
RESULTS 
Sample Characteristics 
 Table 2 provides demographics, HIV disease characteristics, depressive symptoms, 
and rates of neurocognitive impairment across the three groups. Participants were 
predominantly male (81%) with a mean age of 44.2 years. Of the 288 study participants, 130 
(45%) were neurocognitively impaired and rates of impairment across comorbidity group 
demonstrated a stair-step pattern (i.e., incidental < contributing < confounding) similar to that 
of the total CHARTER cohort[1]. As expected, confounded participants reported the most 
depressive symptoms and had the lowest estimated premorbid verbal IQs and education 
levels. Similarly, confounded participants had a significantly higher rate of any lifetime 
substance use disorder (97%) than non-confounded participants (Table 1), although none met 
criteria for current substance use disorder. Groups did not differ on HIV disease 
characteristics, with the full sample demonstrating evidence of cART-induced immune 
reconstitution based on active ARV use (75%) and higher current CD4 counts (median = 459 
cells/mm3) compared to low nadir CD4 counts (median = 152 cells/mm3) and AIDS 
diagnoses (67%). 50% of the sample had detectable plasma HIV RNA (≥50 copies/ml) and 
31% (175/255) had detectable CSF HIV RNA.  
Structural MRI, comorbidity groups, and age 
 Effect size estimates for comorbidity group, age, and their interaction in regression 
models for each structural measure are provided in Table 3. Confounded participants 
exhibited evidence of greater brain abnormality across all structural measures, with 
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significantly smaller volumes of cortical gray matter (vs. incidental) and more abnormal 
white matter (vs. incidental and contributing) and ventricular CSF (vs. incidental). Compared 
to the incidental group, the contributing group displayed significantly smaller volumes of 
cortical gray matter volumes (β=-0.08, p=0.01) and larger volumes of ventricular CSF 
(β=0.14, p=0.02) resulting in stair-step patterns of greater structural damage with increasing 
comorbidity burden.  
The deleterious impact of severe comorbidity burden on brain structure was 
exacerbated with increasing age (Table 3; Figure 1): compared to the effect of age in the 
contributing group, older age in the confounded group was associated with more abnormal 
white matter (β=0.48 vs. β=0.25; p=.017), less total white matter (β=-0.35 vs. β=-0.19; 
p=.015), and less subcortical gray matter (β=-0.54 vs. β=-0.32; p=.039). Similarly, the 
negative effect of age on total white matter volume was greater in confounded participants 
compared to incidental participants (β=-0.54 vs. β=-0.23; p=.006). In contrast, older age was 
associated with less cortical gray matter for incidental (β=-0.26; p<.001) and contributing 
(β=-0.19; p<.001) groups, while confounded participants displayed low cortical gray matter 
volumes at a younger age and demonstrated no further age-related effect (β=-0.04; p=.644). 
While age did not moderate the effect of comorbidity group on ventricular and sulcal CSF 
volumes, older age predicted larger ventricular (β=0.29; p<.001) and sulcal CSF volumes 
(β=0.34; p<.001) independent of comorbidity group.   
To examine potential attenuation of age-related comorbidity group effects, we 
covaried for individual comorbidities that differed in prevalence across age. Increasing age 
was associated with greater likelihood of hypertension (OR=1.08; p<.001), diabetes 
(OR=1.05; p=.039), hyperlipidemia (OR=1.06; p=.026), hepatitis C (OR=1.08; p<.001), and 
lifetime alcohol use disorder (OR=1.03; p=.040), as well as lower likelihood of lifetime 
methamphetamine use disorder (OR=0.93; p<.001). However, covarying for these age-related 
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comorbidities did not attenuate any of the aforementioned significant comorbidity group by 
age interaction effects (all ps<.05).  
Finally, multivariable regression models were conducted to explore the potential 
interactive effects of age and specific conditions on imaging outcomes that were significantly 
predicted by the overall comorbidity group by age interaction analyses. While these analyses 
are not meant to be definitive association studies, they may shed light on the interpretation of 
findings within this manuscript and guide future explorations. Significant individual 
comorbidity by age interaction effects followed similar patterns to those detected in the 
overall comorbidity group by age interaction analyses. Specifically, the deleterious effect of 
age on abnormal white matter was significantly stronger in participants with hypertension 
(β=0.39 vs. β=0.08; p=.047) and hepatitis C co-infection (β=0.39 vs. β=0.08; p=.035). 
Moreover, older age was associated with less cortical gray matter for participants without a 
history of special education (β=-0.25; p<.001) or head trauma (β=-0.25; p<.001), yet older 
age did not relate to cortical gray matter volume for participants with a history of special 
education (β=-0.00; p=.927) or head trauma (β=-0.09; p=.200). 
MRS, comorbidity groups, and age 
 Significant main effect size estimates of comorbidity group and age for MRS 
outcomes are presented in Table 4. Comorbidity group was significantly associated with N-
acetylaspartate and choline in FWM as well as N-acetylaspartate in BG (Table 4). 
Specifically, compared to the incidental group, confounded participants displayed 
significantly lower levels of N-acetylaspartate in FWM and BG as well as a trend toward 
higher levels of myo-inositol in BG (p=.052). Compared to the contributing group, 
confounded participants displayed lower levels of N-acetylaspartate in BG and higher levels 
of choline in FWM. The contributing group did not significantly differ from the incidental 
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group for any MRS outcome. Independent of comorbidity group, older participants had lower 
levels of N-acetylaspartate in FWM and higher levels of choline and myo-inositol in both 
FWM and FGM. No comorbidity group by age interactions were detected for MRS 
outcomes. 
DISCUSSION 
 The present study examined the cerebral impact of comorbidity burden and age in 
PLWH enrolled in the multi-site CHARTER study. We have previously reported on the 
neuroimaging correlates of HAND in PLWH without confounding neurocognitive 
comorbidities[16, 17]. Unlike most neuroAIDS studies that aim to isolate HIV-specific 
mechanisms of CNS injury and therefore exclude confounded individuals, we deliberately 
included confounded individuals as they may represent a particularly vulnerable and 
substantial subpopulation of PLWH[1]. Our findings indicate that PLWH with comorbidities 
severe enough to preclude a diagnosis of HAND display greater brain abnormalities than 
those with minimal-to-moderate comorbidity burdens. Specifically, confounded PLWH 
demonstrated evidence of lower neuronal integrity and structural volumes as well as more 
neuroinflammation in cortical, subcortical, and white matter tissues. Importantly, we 
demonstrate conditional effects of age on the relationship between comorbidity burden and 
brain integrity such that older age and severe comorbidities synergistically contribute to 
subcortical and white matter tissue injury. In addition to prior CHARTER studies 
documenting that confounded PLWH are at greater risk for neurocognitive and everyday 
functional impairment at baseline[1] as well as neurocognitive decline over an average course 
of three years[25], our findings demonstrate distinct neurological differences across 
comorbidity classifications and underscore the importance of including these classifications 
during HAND-diagnostic decision making.  
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cART-era volumetric studies report cortical and subcortical gray matter atrophy, 
white matter volume loss and microstructural abnormalities, and more abnormal white matter 
in PLWH compared to seronegative controls[5, 15, 26, 27]. Two recent meta-analyses from 
O’Connor and colleagues provide further evidence for HIV-related neurostructural damage, 
with the most reliable and prominent effects occurring in total brain volume, gray matter 
volume, and CSF volume[28, 29]. The observation that confounded PLWH had greater 
structural brain abnormalities than incidental and contributing PLWH is not surprising and 
validates the relevance of comorbidities to brain integrity. The source of variability in 
cortical, subcortical, and white matter volumes across comorbidity classifications is likely 
multifactorial. By definition, confounded individuals exhibit higher rates of non-HIV-related 
comorbidities, including neurodevelopmental, cerebrovascular, and systemic medical 
conditions. Cardiometabolic disorders (e.g., hypertension, diabetes mellitus) and hepatitis C 
co-infection are examples of conditions among confounded individuals that are known to 
contribute to CNS dysfunction among PLWH as well as the general population[30-36]. 
Furthermore, these conditions increase with age and may therefore help explain why older 
confounded PLWH demonstrate the strongest evidence of brain injury. Our individual 
comorbidity by age interaction analyses suggest a role for hypertension and hepatitis C in 
driving our age-related findings, as the deleterious effect of age on abnormal white matter 
was strongest in participants with these comorbid conditions. However, our comorbidity 
group by age findings remained significant after adjusting for individual conditions that were 
associated with age, which suggests that a confounded classification reflects broad 
vulnerability to age-related brain injury that may not be fully explained by any single 
comorbid condition. More work is needed to determine whether the brain abnormalities 
present in older, confounded PLWH are more strongly linked to comorbidities of aging or 
“legacy” effects of conditions acquired during younger age.  
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Contrary to expectations, younger confounded PLWH displayed similarly low cortical 
gray matter volumes relative to older confounded PLWH, whereas older age predicted lower 
cortical volumes among non-confounded PLWH. Examination of model estimates (Table 3) 
and visual inspection of simple slopes (Figure 1, panel D) suggest that the predicted cortical 
volume of a 35-year old confounded PLWH closely matches that of a non-confounded 
PLWH in their early 50’s. One potential explanation for this finding is the presence of non-
age-related conditions that impact cortical structure among confounded participants, 
including learning disabilities[37], neurotrauma[38], and substance-related complications[39]. 
Notably, age did not significantly predict cortical gray matter in patients with low estimated 
premorbid IQ or head trauma, suggesting that the low volumes of cortical gray matter 
observed among younger confounded participants may reflect longstanding differences in 
structural brain integrity as well as acquisition of acute brain insults.  
Notably, a stair-step pattern was observed by which increasing comorbidity burden 
was associated with smaller volumes of cortical gray matter, accompanied by larger volumes 
of ventricular CSF. However, no other significant structural nor neurochemical differences 
were detected between contributing and incidental participants, suggesting that moderate 
comorbidity burden is preferentially sensitive to our measure of cortical gray matter. Relative 
to the incidental group, the smaller cortical volume detected in the contributing group may 
confer risk of neurocognitive dysfunction as we observed significantly higher rates of 
neurocognitive impairment among contributing (52%) versus incidental (35%) participants. 
Although we observed the highest prevalence of neurocognitive impairment in confounded 
participants (83%), confounded participants displayed widespread neuroanatomical 
alterations that could also explain the presence of neurocognitive deficits. Furthermore, while 
the confounded group displayed distinct patterns of age-related effects on brain structure 
compared to non-confounded groups, the effect of age was similar between the incidental and 
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contributing groups. The striking pattern of CNS injury in confounded PLWH, compared to 
the similar neuroanatomical profiles of incidental and contributing participants, does not 
indicate comorbidity group differences in underlying HIV-related neurotoxicity; however, the 
unique impact of confounding neurocognitive comorbidities on brain integrity aligns with the 
Frascati comorbidity classification distinction between confounded and non-confounded 
PLWH.  
Confounded participants also exhibited patterns of neurometabolic dysfunction in 
FWM and BG compared to incidental and contributing participants. Our results 
demonstrating lower levels of N-acetylaspartate (FWM and BG) and higher levels of choline 
(FWM) and myo-inositol (BG) in confounded PLWH parallel past studies, in which 
confounding conditions were considered exclusionary, reporting that cART-era PLWH 
experience reductions in neuronal integrity with accompanying elevations in 
neuroinflammation across cortical and subcortical regions[40-42]. Investigating the independent 
and interactive effects of HIV status, cardiovascular risk, and age on MRS outcomes, Cysique 
et al.[43] reported that acute cardiovascular events predicted lower N-acetylaspartate and 
higher myo-inositol in the posterior cingulate cortex, yet these effects were not moderated by 
age. Although older age independently predicted lower N-acetylaspartate (FWM) and higher 
choline and myo-inositol (FWM and FGM) in our sample, we similarly did not detect any 
moderating effects of age on the association between comorbidity burden and MRS 
outcomes. In addition to enhanced cerebrovascular risk, our results may be partly explained 
by greater prevalence of substance use, systemic medical conditions (e.g., hepatitis c co-
infection), and head trauma among confounded participants; all aforementioned 
comorbidities have been linked to neurochemical abnormalities and neurocognitive 
impairment in HIV-infection[39, 44, 45]. 
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Our analyses comparing comorbidity groups on HIV disease and treatment 
characteristics suggest that the observed impact of comorbidity burden on imaging outcomes 
is not primarily attributable to group differences in systemic HIV disease severity. All three 
comorbidity groups displayed similar patterns of cART usage, immune recovery (e.g., 
difference between nadir and current CD4), and plasma and CSF viral load levels. These 
results are consistent with the larger baseline CHARTER study in which comorbidity groups 
did not differ on most HIV-related neuromedical parameters, with the exception of lower 
nadir CD4 counts and more AIDS diagnoses in confounded participants compared to 
incidental participants[1]. Given that prior studies have demonstrated strong associations 
between increasing HIV disease severity (e.g., higher viral load and lower nadir CD4) and 
smaller brain volume[16, 21, 46], as well as smaller effects of HIV serostatus on brain volume in 
cART-era cohorts[29], the deleterious effect of increasing comorbidity burden on brain 
integrity is noteworthy in the absence of group differences in HIV disease burden and 
treatment characteristics. In the overall CHARTER sample, lower nadir CD4 counts, AIDS 
diagnosis, and viral suppression on active cART use were related to higher rates of 
neurocognitive impairment among incidental participants only[1]. Whether similar conditional 
effects of HIV disease parameters and comorbidity burden hold in the context of 
neuroimaging remains unknown and is worthy of future investigation.  
We acknowledge several limitations to this study. Although our results highlight the 
clinical relevance of comorbidity classifications among PLWH, we cannot empirically 
determine the specificity of our findings to PLWH given the absence of a demographically-
comparable control group. Next, our global volumetric MRI measures may be less 
informative with regard to specific mechanisms of neural injury compared to newer MRI 
techniques that assess cerebral connectivity (e.g., functional MRI, diffusion tensor imaging), 
however, our estimates of cortical and subcortical gray matter as well as abnormal and total 
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white matter permit the quantification of broad neuroanatomical features that are sensitive to 
effects of both HIV and aging[16, 21, 47, 48]. The cross-sectional and associative nature of our 
study makes it difficult to disentangle the interactive effects of aging and comorbidity burden 
from longstanding differences in brain integrity, a topic which could be more adequately 
addressed with a longitudinal design. Prior longitudinal studies have examined the interaction 
between HIV serostatus and age/time on neuroimaging outcomes, with some reporting HIV-
related accelerated aging in selective cortical tissues[13] and others failing to detect 
interactions between HIV and aging[49]. Previously published longitudinal neurocognitive 
findings in CHARTER revealed that a confounded comorbidity classification independently 
predicted incident neurocognitive decline, suggesting that comorbidity burden influences the 
stability of CNS function across time[25]. However, we are not aware of any studies that have 
examined the role of comorbidity burden on longitudinal changes in brain integrity in PLWH. 
Nevertheless, our inclusive approach to comorbidity classifications demonstrates robust 
sensitivity to neurological dysfunction, consistent with other methods of quantifying age-
related acquisition of multi-system damage (e.g., VACS index[50], frailty index[51]). Finally, 
although we detected a number of significant differences between confounded and non-
confounded PLWH, the relatively small number of confounded participants hinders our 
ability to conduct more sophisticated models with additional covariates and interaction terms.  
Taken together, our findings lend further support to the inclusion of Frascati 
comorbidity classifications during HAND diagnostic decision-making. Those with severe 
comorbidity burden exhibit the most extensive evidence of abnormal neurocognitive 
performance and abnormal neuroimaging findings, despite having similar profiles of HIV 
disease severity to those with minimal/mild-to-moderate comorbidity burden. In contrast, the 
neuroimaging profiles of participants with minimal/mild comorbidity burden were mostly 
comparable to those with moderate comorbidity burden. Our results suggest that the presence 
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of severe comorbid conditions contributes to neurological dysfunction above and beyond the 
effects of HIV, thus highlighting the need to identify and account for such conditions during 
clinical evaluation. Furthermore, confounded PLWH may be particularly vulnerable to age-
related subcortical gray and white matter tissue injury, warranting increased clinical 
monitoring to this population as it ages. Given the rising prevalence of older PLWH, clinical 
efforts aimed at reducing the frequency (e.g., exercise) and severity (e.g., medication 
adherence) of comorbid conditions may mitigate the public health costs associated with 
treating HIV-related neurological dysfunction.  
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Table 1 Comorbid condition rates by comorbidity group. 
 A. Incidental, n = 
176 
B. Contributing, 
n = 77 
C. Confounded, 
n = 35 
Pair-wise 
comparisonsa 
Low estimated 
premorbid IQb 
17 (9.7%) 17 (22.1%) 11 (31.4%) A < B, C 
Special 
educationc 
6 (3.4%) 7 (9.1%) 9 (25.7%) A < C 
Other school 
problems 
10 (5.7%) 29 (37.7%) 17 (48.6%) A < B, C 
Head traumad 10 (5.7%) 23 (29.9%) 18 (51.4%) A < B, C 
Cerebrovascular 
eventse 
0 (0%) 0 (0%) 7 (20%) A, B < C 
Epilepsy 0 (0%) 0 (0%) 1 (2.9%)  
Other seizure 
history 
1 (0.6%) 9 (11.7%) 6 (17.1%) A < B, C 
Systemic 
medical diseasef 
48 (27.3%) 42 (55.3%) 29 (82.9%) A < B < C 
CNS 
opportunistic 
disease 
7 (4%) 4 (5.2%) 1 (2.9%)  
Lifetime major 
depression 
99 (56.3%) 45 (58.4%) 22 (62.9%)  
Current major 
depression 
18 (10.2%) 7 (9.2%) 3 (8.6%)  
Psychotic 
disorderg 
3 (1.7%) 11 (14.3%) 4 (11.4%)  
[0,1-5]Lifetime substance use disorders 
   Any substance 132 (75%) 55 (71.4%) 34 (97.1%) A, B < C 
   Alcohol 103 (58.5%) 34 (44.2%) 26 (74.3%)  
   Cannabis 49 (27.8%) 21 (27.3%) 13 (37.1%)  
   Cocaine 73 (41.5%) 36 (46.8%) 24 (68.6%) A < C 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
   Opioid 25 (14.2%) 20 (26%) 8 (22.9%)  
   Methamphetamine 31 (17.6%) 13 (16.9%) 6 (17.1%)  
   Hallucinogen 11 (6.3%) 3 (3.9%) 2 (5.7%)  
   Sedative 15 (8.5%) 5 (6.5%) 5 (14.3%)  
   Inhalant 6 (3.4%) 2 (2.6%) 2 (5.7%)  
   Other 7 (4%) 2 (2.6%) 2 (5.7%)  
Substance overdose 
with complicationsh 
2 (1.1%) 10 (13%) 7 (20%) A < B, C 
Recent substance 
usei 
21 (11.9%) 28 (36.4%) 8 (22.9%) A < B 
Total comorbid 
conditions, m (SD) 
3.0 (2.00) 4.7 (2.31) 6.5 (2.16) A < B < C 
aAll reported pair-wise differences are significant after Bonferroni-adjustment (α = 0.05/3 = 
0.0167). 
bWide Range Achievement Test reading subtest, 3rd edition less than 80. 
cSpecial tutoring or grade retention. 
dTraumatic head injury with loss of consciousness or other neurologic sequelae. 
eRange from TIAs to completed strokes. 
fPotentially significant medical comorbidity (e.g., diabetes mellitus, myocardial infarction, 
hepatitis C infection). 
gSchizophrenia or bipolar disorder. 
hOverdose requiring cardiopulmonary resuscitation or hospitalization. 
iPositive breathalyzer or urine toxicology for psychoactive substances on day of testing. 
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Table 2 Demographic and clinical characteristics by comorbidity group. 
 A. 
Incidental, 
n = 176 
B. 
Contributing, 
n = 77 
C. Confounded, n 
= 35 
P Pair-wise 
compariso
nsa 
[0,1-6]Demographics 
   Age (years) 43.6 (8.00) 45.3 (7.37) 45 (7.05) 0.24  
   Education 
(years) 
13.3 (2.34) 12.7 (2.42) 11.5 (3.11) <0.001 A > C 
   Estimated 
premorbid IQb 
97.2 
(12.34) 
91.8 (15.66) 84.8 (20.15) <0.001 A > B > C
   Sex (male) 147 (84%) 58 (75%) 27 (77%) 0.28  
   Ethnicity    0.23  
      White 79 (45%) 28 (36%) 10 (29%)   
      Black 78 (44%) 35 (45%) 21 (60%)   
      Hispanic 17 (10%) 11 (14%) 4 (11%)   
      Other 2 (1%) 3 (4%) 0 (0%)   
[0,1-6]Neurobehavioral 
   
Neurocognitive 
impairment 
61 (35%) 40 (52%) 29 (83%) <0.001 A < B < C
   BDI-II 8 [4–17.75] 8 [4–17] 15 [8–23] 0.04 A < C 
[0,1-6]HIV disease characteristics 
   AIDS 
diagnosis 
117 (66%) 53 (69%) 23 (66%) 0.92  
   Estimated 
duration of 
infection (years) 
10.7 (6.01) 11.7 (6.38) 12.7 (5.78) 0.13  
   Nadir CD4+ 
cell count 
155 [30.5–
299] 
120 [20.5–
255.5] 
158 [25–240] 0.48  
   Current CD4+ 449.5 [291– 463 [268.25– 461 [274–826] 0.21  
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cell count 620.5] 627.25] 
   ARV status    0.20  
      Currently 
using 
133 (76%) 60 (78%) 24 (69%)   
    Never used 17 (10%) 10 (13%) 2 (6%)   
     Past use 26 (15%) 7 (9%) 9 (26%)   
[0,1-6]   Plasma viral load 
  Cells/ml (log) 1.70 [1.70–
4.00] 
1.75 [1.70–
3.63] 
1.84 [1.70–4.18] 0.96  
      Detectable 89 (51%) 37 (48%) 17 (50%) 0.90  
[0,1-6]   CSF viral loadc 
      Cells/ml 
(log) 
1.70 [1.70–
2.30] 
1.70 [1.70–
1.84] 
1.70 [1.70–3.06] 0.23  
      Detectable 49 (31%) 18 (26%) 13 (43%) 0.26  
Values are presented as mean (SD), median [IQR], or N (%). ARV, antiretroviral therapy; 
BDI-II, Beck-Depression Inventory-II total score. 
aPair-wise comparisons were examined using Tukey’s H.S.D. (α = 0.05) for continuous 
outcomes and Bonferroni adjustments (α = 0.05/3 = 0.0167) for dichotomous outcomes. 
bWide Range Achievement Test reading subtest, 3rd edition. 
cN = 175. 
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Table 3 Standardized beta effect size estimates for structural MRI measures. 
Predictor Cortical 
gray 
Subcortical 
gray 
Abnormal 
white 
Total white Ventricular 
CSF 
Sulcal CSF 
Incidentala 0.16* 0.14 −0.26** 0.02 −0.27** −0.14 
Contributin
ga 
0.07 0.04 −0.20*** 0.04 −0.11 −0.06 
Ageb −0.04 −0.54* 0.48** −0.35** 0.42*** 0.43** 
Incidental × 
age 
−0.18*** 0.20 −0.26 0.31** −0.12 −0.06 
Contributin
g × age 
−0.07 0.22*** −0.23*** 0.16*** −0.05 −0.08 
Reported values are standardized regression coefficients for each parameter of interest in 
multivariable regression analyses predicting structural MRI measures. Significant 
comorbidity × age interaction plots are presented in Fig. 1. 
aCompared with confounded. Estimates fixed at average age. 
bRepresents effect of age for confounded group only. 
*P < 0.001. 
**P < 0.01. 
***P < 0.05. 
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Table 4 Standardized beta effect size estimates for select magnetic resonance spectroscopy 
measures. 
 [0,2-3]Basal ganglia [0,4-6]Frontal white matter [0,7-8]Frontal gray 
matter 
Predictor NAA Myoinositol NA
A 
Choline Myoinosit
ol 
Cholin
e 
Myoinositol
Incidentala 0.27* −0.19** 0.23*
** 
−0.14 0.04 −0.11 0.05 
Contributin
ga 
0.26* −0.11 0.17*
* 
−0.19*** 0.06 −0.13 0.12 
Age −0.09 0.08 −
0.16*
0.15*** 0.21**** 0.14*** 0.13*** 
No significant comorbidity and age interactions were detected. Reported values are 
standardized regression coefficients for each parameter of interest in multivariable regression 
analyses predicting MRS measures. Sample sizes: Basal ganglia N-acetylaspartate (n = 248) 
and myoinositol (n = 240); frontal white matter N-acetylaspartate (n = 265), choline (n = 
264), and myoinositol (n = 252); frontal gray matter choline (n = 274) and myoinositol (n = 
271). MRS, magnetic resonance spectroscopy; NAA, N-acetylaspartate. 
aCompared with confounded. 
*P < 0.01. 
**P < 0.10. 
***P < 0.05. 
****P < 0.001. 
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 FIGURE LEGEND 
Figure 1 
Title: Age moderates the relationships between comorbidity burden and brain structure.  
Caption: Interaction between age and comorbidity group predicting (A) abnormal white 
matter, (B) total white matter, (C) subcortical gray matter, and (D) cortical gray matter. All 
structural volumes are log-transformed. 
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